Protocol Ledger

NCT04708782 · Phase III · COMPLETED

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Interventional Phase III clinical trial protocol NCT04708782 sponsored by United Therapeutics in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-01 Enrollment: 598 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04708782
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)598 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04708782
Protocol FieldVerified Registry Value
NCT IdentifierNCT04708782
Consolidated Lead SponsorUnited Therapeutics
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment598 participants (ACTUAL)
Registered Start Date2021-06-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04708782
Hospital Research SiteLocationSite Profile
University of ArizonaTucson, AZOpen Hospital Dossier ->
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI